Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sola Diagnostics
Zams, Tyrol, Austria
- Ownership
- Private
- Development stage
- Other
01
Overview
Sola Diagnostics develops and commercializes non‑invasive epigenetic diagnostics for women’s cancers, including the WID-easy test for early uterine/womb cancer detection, which is already on the market in Austria, Switzerland, and the UK and aims to replace most diagnostic hysteroscopy and curettage procedures[1][3].
- Therapeutic areas
- Oncology
- Modalities
- DeviceNon-pharmacological therapy
- Industry
- Molecular Diagnostics
02
Partnerships
University College London (technology origin and clinical research collaboration)[4]University of Innsbruck – EUTOPS Institute (ongoing epigenetics research and technology development)[4]
Beyond the preview
Go deeper on Sola Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sola Diagnostics.